Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like raw 264.7 cells

Inflammation

Volumn 35, Issue 4, 2012, Pages 1411-1418

  Mao, Xin ^a   Pan, Xiaoyun ^a   Peng, Xiaochun ^a   Cheng, Tao ^a   Zhang, Xianlong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Aseptic loosening; Bortezomib; Iflammation; Macrophage; Wear particle

Indexed keywords

BORTEZOMIB; CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEASOME INHIBITOR; TITANIUM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL LINE; CELL STIMULATION; CELL STRAIN RAW 264.7; CONCENTRATION RESPONSE; CONTROLLED STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PROSTHESIS LOOSENING; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BORONIC ACIDS; CELL LINE; CELL SURVIVAL; CHEMOKINE CCL2; CYCLOOXYGENASE 2; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGE INFLAMMATORY PROTEINS; MACROPHAGES; MICE; NITRIC OXIDE SYNTHASE TYPE II; PROTEASOME INHIBITORS; PYRAZINES; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 84866645401     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9454-5     Document Type: Article

References (34)

1. Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11): 1271-1286.
2. Berry, D., W. Harmsen, M. Cabanela, and B. Morrey. 2002. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: Factors affecting survivorship of acetabular and femoral components. The Journal of Bone and Joint Surgery. American Volume 84(2): 171-177.
3. Sundfeldt, M., L.V. Carlsson, C.B. Johansson, P. Thomsen, and C. Gretzer. 2006. Aseptic loosening, not only a question of wear: A review of different theories. Acta Orthopaedica 77(2): 177-197.
4. Ren, W., D. Markel, R. Schwendener, Y. Ding, B. Wu, and P. Wooley. 2008. Macrophage depletion diminishes implant-wearinduced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research. Part A 85(4): 1043-1051.
5. Sabokbar, A., O. Kudo, and N. Athanasou. 2003. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. Journal of Orthopaedic Research 21(1): 73-80.
6. Wang, C.T., Y.T. Lin, B.L. Chiang, S.S. Lee, and S.M. Hou. 2010. Over-expression of receptor activator of nuclear factor-[kappa] B ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty. Biomaterials 31(1): 77-82.
7. Im, G.I., and J.D. Han. 2001. Suppressive effects of interleukin-4 and interleukin-10 on the production of proinflammatory cytokines induced by titanium-Alloy particles. Journal of Biomedical Materials Research 58(5): 531-536.
8. Sabat, R., G. Grütz, K. Warszawska, S. Kirsch, E. Witte, K. Wolk, and J. Geginat. 2010. Biology of interleukin-10. Cytokine & Growth Factor Reviews 21(5): 331-344.
9. Fritz, E.A., T.T. Glant, C. Vermes, J.J. Jacobs, and K.A. Roebuck. 2006. Chemokine gene activation in human bone marrow-derived osteoblasts following exposure to particulate wear debris. Journal of Biomedical Materials Research. Part A 77(1): 192-201.
10. Huang, Z., T. Ma, P.G. Ren, R.L. Smith, and S.B. Goodman. 2010. Effects of orthopedic polymer particles on chemotaxis of macrophages and mesenchymal stem cells. Journal of Biomedical Materials Research. Part A 94(4): 1264-1269.
11. Hukkanen, M., S. Corbett, J. Batten, Y. Konttinen, I. McCarthy, J. Maclouf, S. Santavirta, S. Hughes, and J. Polak. 1997. Aseptic loosening of total hip replacement: Macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure. Journal of Bone and Joint Surgery 79(3): 467-474.
12. Elliott, P.J., and J.S. Ross. 2001. The proteasome. American Journal of Clinical Pathology 116(5): 637-646.
13. Bedford, L., S. Paine, P.W. Sheppard, R.J. Mayer, and J. Roelofs. 2010. Assembly, structure, and function of the 26S proteasome. Trends in Cell Biology 20(7): 391-401.
14. Elliott, P.J., T.M. Zollner, and W.H. Boehncke. 2003. Proteasome inhibition: A new anti-inflammatory strategy. Journal of Molecular Medicine 81(4): 235-245.
15. Richardson, P.G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and R. Alexanian. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348 (26): 2609-2617.
16. Yannaki, E., A. Papadopoulou, E. Athanasiou, P. Kaloyannidis, A. Paraskeva, D. Bougiouklis, P. Palladas, M. Yiangou, and A. Anagnostopoulos. 2010. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvantinduced arthritis in rats. Arthritis and Rheumatism 62(11): 3277-3288.
17. Lee, S.W., J.H. Kim, Y.B. Park, and S.K. Lee. 2009. Bortezomib attenuates murine collagen-induced arthritis. Annals of the Rheumatic Diseases 68(11): 1761-1767.
18. Rakshit, D., K. Ly, T. Sengupta, B. Nestor, T. Sculco, L. Ivashkiv, and P. Purdue. 2006. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. The Journal of Bone and Joint Surgery. American Volume 88(4): 788-799.
19. Sethi, R.K., M.J. Neavyn, H.E. Rubash, and A.S. Shanbhag. 2003. Macrophage response to cross-linked and conventional UHMWPE. Biomaterials 24(15): 2561-2573.
20. Lee, S., C. Woo, J. Chang, and J. Kim. 2003. Roles of Rac and cytosolic phospholipase A2 in the intracellular signalling in response to titanium particles. Cellular Signalling 15(3): 339-345.
21. Möller, B., and P.M. Villiger. 2006. Inhibition of IL-1, IL-6, and TNF-A in immune-mediated inflammatory diseases. Springer Seminars in Immunopathology 27(4): 391-408.
22. Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. The Journal of Experimental Medicine 191(2): 313-320.
23. Caicedo, M., J.J. Jacobs, and N.J. Hallab. 2010. Inflammatory bone loss in joint replacements: The mechanisms. Journal Musculoskeletal Medicine 27: 209-216.
24. Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunology Today 15(2): 74-80.
25. Suzuki, Y., T. Nishiyama, K. Hasuda, T. Fujishiro, T. Niikura, S. Hayashi, S. Hashimoto, and M. Kurosaka. 2007. Effect of etidronate on COX-2 expression and PGE 2 production in macrophage-like RAW 264.7 cells stimulated by titanium particles. Journal of Orthopaedic Science 12(6): 568-577.
26. Ragab, A.A., J.L. Nalepka, Y. Bi, and E.M. Greenfield. 2002. Cytokines synergistically induce osteoclast differentiation: Support by immortalized or normal calvarial cells. American Journal of Physiology. Cell Physiology 283(3): C679-C687.
27. Goodman, S.B., and T. Ma. 2010. Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 31(19): 5045-5050.
28. Harris, S.G., J. Padilla, L. Koumas, D. Ray, and R.P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends in Immunology 23(3): 144-150.
29. Steeve, K.T., P. Marc, T. Sandrine, H. Dominique, and F. Yannick. 2004. IL-6, RANKL, TNF-Alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine & Growth Factor Reviews 15(1): 49-60.
30. Krakauer, T. 2004. Molecular therapeutic targets in inflammation: Cyclooxygenase and NF-kappaB. Current Drug Targets. Inflammation and Allergy 3(3): 317-324.
31. Smallie, T., G. Ricchetti, N.J. Horwood, M. Feldmann, A.R. Clark, and L.M. Williams. 2010. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. The Journal of Experimental Medicine 207(10): 2081-2088.
32. Lentsch, A.B., T.P. Shanley, V. Sarma, and P.A. Ward. 1997. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. The Journal of Clinical Investigation 100(10): 2443-2448.
33. Su, Y.W., W.F. Chiou, S.H. Chao, M.H. Lee, C.C. Chen, and Y.C. Tsai. 2011. Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF-kappaB and AP-1 signaling pathways. International Immunopharmacology 11(9): 1166-1172.
34. Goldberg, A. 2007. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochemical Society Transactions 35: 12-17.